The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the risk of severe post-treatment (tx) cancer-related fatigue (CRF) among breast cancer survivors (BCS) in the CANcer TOxicity (CANTO) cohort.
 
Antonio Di Meglio
Honoraria - Thermo Fisher Scientific
 
Julie Havas
No Relationships to Disclose
 
Elise Martin
No Relationships to Disclose
 
Barbara Pistilli
No Relationships to Disclose
 
Gwenn Menvielle
No Relationships to Disclose
 
Agnes Dumas
No Relationships to Disclose
 
Cecile Charles
No Relationships to Disclose
 
Sibille Everhard
No Relationships to Disclose
 
Anne-Laure Martin
No Relationships to Disclose
 
Charles Coutant
No Relationships to Disclose
 
Carole Tarpin
No Relationships to Disclose
 
Laurence Vanlemmens
No Relationships to Disclose
 
Christelle Levy
No Relationships to Disclose
 
Olivier Rigal
No Relationships to Disclose
 
Suzette Delaloge
Consulting or Advisory Role - AstraZeneca (Inst); Pierre Fabre (Inst)
Research Funding - AstraZeneca (Inst); Exact Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Patricia A. Ganz
Leadership - Intrinsic LifeSciences (I)
Stock and Other Ownership Interests - Abbott Laboratories; GlaxoSmithKline; Intrinsic LifeSciences (I); Johnson & Johnson; Merck; Novartis; Pfizer; Silarus Therapeutics (I); Teva; xenon pharma (I)
Consulting or Advisory Role - Akebia Therapeutics (I); Ambys Medicines (I); American Regent (I); Astellas Pharma (I); Blue Note Therapeutics; Disc Medicine (I); GlaxoSmithKline (I); Global Blood Therapeutics (I); Gossamer Bio (I); InformedDNA; Ionis Pharmaceuticals (I); Protagonist Therapeutics (I); Regeneron (I); Rockwell Medical Technologies Inc (I); Sierra Oncology (I); Vifor Pharma (I)
Research Funding - Sierra Oncology (I)
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I)
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
Travel, Accommodations, Expenses - Novartis
 
Fabrice Andre
Stock and Other Ownership Interests - PEGASCY
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Stefan Michiels
Consulting or Advisory Role - Amaris Consulting; Biophytis; IDDI; Janssen-Cilag France; Sensorion; SERVIER; Yuhan
Patents, Royalties, Other Intellectual Property - Co-inventor of patent WO2018002385A1 on prognostic gene score in early breast cancer
 
Ines Maria Vaz Duarte Luis
Honoraria - Amgen (Inst); AstraZeneca (Inst); Pfizer (Inst)